Poonam Yadav, Kajal Rana, Viviani Nardini, Ali Khan, Trishna Pani, Animesh Kar, Dolly Jain, Ruchira Chakraborty, Ragini Singh, Somesh K Jha, Devashish Mehta, Harsh Sharma, Ravi Datta Sharma, S V S Deo, Sagar Sengupta, Veena S Patil, Lúcia Helena Faccioli, Ujjaini Dasgupta, Avinash Bajaj
Cancer treatment is challenged due to immunosuppressive inflammatory tumour microenvironment (TME) caused by infiltration of tumour-promoting and inhibition of tumour-inhibiting immune cells. Here, we report the engineering of chimeric nanomicelles (NMs) targeting the cell proliferation using docetaxel (DTX) and inflammation using dexamethasone (DEX) that alters the immunosuppressive TME. We show that a combination of phospholipid-DTX conjugate and PEGylated-lipid-DEX conjugate can self-assemble to form sub-100 nm chimeric NMs (DTX-DEX NMs)...
March 8, 2024: Journal of Controlled Release